[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 33 of about 33
1. Sniezek JC, Holtel M: Rare tumors of the thyroid gland. Otolaryngol Clin North Am; 2003 Feb;36(1):107-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although the vast majority of thyroid cancers are well-differentiated and carry an excellent prognosis, several rare tumors occasionally involve the thyroid gland and require unique treatment paradigms.
  • Anaplastic carcinoma of the thyroid is an extremely aggressive neoplasm that is generally best managed with surgery followed by a multimodality regimen of radiotherapy and chemotherapy.
  • Treatment and prognosis of lymphoma of the thyroid varies depending upon the specific pathological subtype, with combination chemotherapy and radiation therapy used primarily.
  • Sarcomas of the thyroid are primarily managed with surgery, although radiation and chemotherapy are indicated in some cases.
  • [MeSH-major] Carcinoma / pathology. Carcinoma, Squamous Cell / pathology. Lymphoma / pathology. Sarcoma / pathology. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12803012.001).
  • [ISSN] 0030-6665
  • [Journal-full-title] Otolaryngologic clinics of North America
  • [ISO-abbreviation] Otolaryngol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 44
  •  go-up   go-down


2. Chen JH, Enloe BM, Weybright P, Campbell N, Dorfman D, Fletcher CD, Cory DG, Singer S: Biochemical correlates of thiazolidinedione-induced adipocyte differentiation by high-resolution magic angle spinning NMR spectroscopy. Magn Reson Med; 2002 Oct;48(4):602-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thiazolidinediones, a class of synthetic ligands to the peroxisome proliferator-activated receptor-gamma, induce terminal adipocyte differentiation of 3T3 F442A cells, and have already been used as alternative therapeutic agents for the treatment of liposarcoma in clinical trials.
  • The biochemical changes occurring in the 3T3 F442A cell line and well-differentiated liposarcoma following induction of adipocyte differentiation with the thiazolidinedione troglitazone were measured using high-resolution magic angle spinning (MAS) nuclear magnetic resonance (NMR) spectroscopy.
  • The molar ratio of PTC to PC increased fourfold in differentiated 3T3 F442A cells compared to undifferentiated cells, suggesting a substantial increase in CTP:phosphocholine cytidylyltransferase activity with differentiation.
  • A 2.8-fold increase in the PTC:PC ratio was observed in the lipoma-like well-differentiated liposarcoma of three patients who were treated with troglitazone when compared to liposarcoma from patients not treated with this drug.
  • Thus, this ratio may be an NMR-detectable marker of troglitazone efficacy and response to differentiation therapy for liposarcoma.
  • [MeSH-major] Adipocytes / metabolism. Cell Differentiation / drug effects. Magnetic Resonance Spectroscopy / methods. Thiazoles / pharmacology. Thiazolidinediones
  • [MeSH-minor] 3T3 Cells. Animals. Antineoplastic Agents / therapeutic use. Cells, Cultured. Chromans / therapeutic use. Flow Cytometry. Humans. Ligands. Liposarcoma / drug therapy. Liposarcoma / metabolism. Mice. Phosphatidylcholines / metabolism. Phosphorylcholine / metabolism. Receptors, Cytoplasmic and Nuclear / metabolism. Transcription Factors / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 Wiley-Liss, Inc.
  • (PMID = 12353276.001).
  • [ISSN] 0740-3194
  • [Journal-full-title] Magnetic resonance in medicine
  • [ISO-abbreviation] Magn Reson Med
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01-CA75720; United States / NCI NIH HHS / CA / R21-CA83759
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Chromans; 0 / Ligands; 0 / Phosphatidylcholines; 0 / Receptors, Cytoplasmic and Nuclear; 0 / Thiazoles; 0 / Thiazolidinediones; 0 / Transcription Factors; 107-73-3 / Phosphorylcholine; 2295-31-0 / 2,4-thiazolidinedione; I66ZZ0ZN0E / troglitazone
  •  go-up   go-down


3. Cho SH, Rhim SC, Hyun SJ, Bae CW, Khang SK: Intradural involvement of multicentric myxoid liposarcoma. J Korean Neurosurg Soc; 2010 Sep;48(3):276-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Liposarcomas are malignant tumors of the soft tissue, with myxoid liposarcoma being the second most common subtype, tending to occur in the limbs, particularly in the thighs.
  • Myxoid liposarcomas have an intermediate prognosis between well-differentiated and pleomorphic tumors.
  • She was histologically diagnosed with small round cell myxoid sarcoma and underwent adjuvant chemotherapy.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21082059.001).
  • [ISSN] 1598-7876
  • [Journal-full-title] Journal of Korean Neurosurgical Society
  • [ISO-abbreviation] J Korean Neurosurg Soc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2966733
  • [Keywords] NOTNLM ; Cervical spine / Metastasis / Multicentric / Myxoid liposarcoma / lntradural
  •  go-up   go-down


Advertisement
4. Takano M, Shibasaki T, Sato K, Aida S, Kikuchi Y: Malignant mixed Mullerian tumor of the uterine corpus with alpha-fetoprotein-producing hepatoid adenocarcinoma component. Gynecol Oncol; 2003 Nov;91(2):444-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: Hepatoid adenocarcinoma is a rare tumor and has the histological coexistence of well-differentiated adenocarcinoma and nests of hepatoid cells with immunoreactivity for alpha-fetoprotein (AFP).
  • Histologically, the tumor was composed of endometrioid adenocarcinoma, neoplastic hepatoid cells, and sarcoma component including leiomyosarcoma and rhabdomyosarcoma.
  • After operation followed by six courses of platinum-based chemotherapy, serum levels of AFP dropped into normal range.

  • Genetic Alliance. consumer health - Malignant mixed Mullerian tumor.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14599882.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / alpha-Fetoproteins
  • [Number-of-references] 17
  •  go-up   go-down


5. Abdelkrim SB, Trabelsi A, Hammedi F, Boudagga MZ, Bdioui A, Jomaa W, Mokni M: Synovial Sarcoma: A Clinicopathological and Radiological Study of 12 Cases Seen Over 18 Years. World J Oncol; 2010 Feb;1(1):14-18
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synovial Sarcoma: A Clinicopathological and Radiological Study of 12 Cases Seen Over 18 Years.
  • Background: Synovial sarcoma is a rare malignant soft tissue tumor characterized by a poor outcome.
  • We report herein our experience concerning synovial sarcoma and review its diagnosis, histology, treatment and prognosis.
  • Methods: This is a retrospective review, from 1990 to 2007, of cases of synovial sarcoma diagnosed at the Department of Pathology, Farhat Hached hospital, Sousse, Tunisia.
  • The clinical, radiological and pathological features as well as treatment modalities and patient's outcome were recorded.
  • Results: From 1990 to 2007, 12 cases of synovial sarcoma have been diagnosed in our department.
  • Patients' mean age at the time of diagnosis was 21 years.
  • Ten patients underwent surgery, in association with adjuvant chemotherapy in 4 cases, one of whom underwent post-operative radiotherapy.
  • Histological subtypes included monophasic synovial sarcoma in 8 cases, biphasic synovial sarcoma in 3 cases and poorly differentiated synovial sarcoma in one case.
  • At the time of analysis, 6 patients were dead with an average follow-up of 18 months.
  • Conclusions: Synovial sarcoma is a rare malignancy with a propensity for young adults and a poor prognosis.
  • Diagnosis can be suggested by radiology and definitive diagnosis is achieved after pathological analysis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Med Sci Monit. 2008 Jun;14(6):CR305-310 [18509273.001]
  • [Cites] Acta Orthop Scand Suppl. 2000 Apr;291:1-28 [10862210.001]
  • [Cites] EMBO J. 1995 May 15;14(10):2333-40 [7539744.001]
  • [Cites] J Clin Oncol. 2004 Oct 15;22(20):4040-50 [15364967.001]
  • [Cites] Eur Radiol. 2003 May;13(5):1125-36 [12695837.001]
  • [Cites] Semin Surg Oncol. 1988;4(1):38-44 [2832924.001]
  • [Cites] Am J Surg Pathol. 1999 Jan;23(1):106-12 [9888710.001]
  • [Cites] J Comput Assist Tomogr. 1997 Sep-Oct;21(5):785-9 [9294576.001]
  • [Cites] ANZ J Surg. 2004 Sep;74(9):727-31 [15379796.001]
  • [Cites] Cancer. 1999 Jun 15;85(12):2596-607 [10375108.001]
  • [Cites] Am J Surg Pathol. 2006 Jun;30(6):721-6 [16723849.001]
  • [Cites] J Pediatr Hematol Oncol. 2005 Apr;27(4):207-11 [15838392.001]
  • [Cites] AJR Am J Roentgenol. 1993 Oct;161(4):827-30 [8396848.001]
  • [Cites] J Surg Oncol. 2008 Mar 15;97(4):314-20 [18286474.001]
  • [Cites] Cancer Genet Cytogenet. 2006 May;167(1):82-8 [16682293.001]
  • [Cites] Cancer. 1965 May;18:613-27 [14278894.001]
  • [Cites] Laryngorhinootologie. 2004 Feb;83(2):96-101 [14999584.001]
  • [Cites] Ann Oncol. 2005 Mar;16(3):437-44 [15653701.001]
  • [Cites] Clin Orthop Relat Res. 2004 Feb;(419):155-61 [15021147.001]
  • [Cites] Cancer. 1990 May 15;65(10):2295-300 [2161280.001]
  • [Cites] J Thorac Imaging. 2003 Apr;18(2):87-93 [12700482.001]
  • [Cites] Clin Imaging. 2005 Jul-Aug;29(4):291-3 [15967324.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):525-34 [11208847.001]
  • [Cites] AJR Am J Roentgenol. 1991 Feb;156(2):337-40 [1846054.001]
  • [Cites] Laryngorhinootologie. 2008 Jul;87(7):498-502 [18231962.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):350-62 [8996162.001]
  • [Cites] Am J Clin Oncol. 2004 Apr;27(2):122-7 [15057149.001]
  • [Cites] Mod Pathol. 2007 Jul;20(7):760-9 [17464314.001]
  • [Cites] Br J Radiol. 2008 Apr;81(964):346-56 [18250123.001]
  • [Cites] J Comput Assist Tomogr. 2004 Jan-Feb;28(1):140-8 [14716248.001]
  • (PMID = 29147174.001).
  • [ISSN] 1920-454X
  • [Journal-full-title] World journal of oncology
  • [ISO-abbreviation] World J Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Keywords] NOTNLM ; Histology / Prognosis / Radiology / Synovial sarcoma / Treatment
  •  go-up   go-down


6. Ishii N, Yonese J, Tsukamoto T, Maezawa T, Fukui I, Ishikawa Y, Aoki N: [Multiple synchronous primary malignant tumors of fibrosarcoma and squamous cell carcinoma in the urinary bladder: a case report]. Nihon Hinyokika Gakkai Zasshi; 2002 Jul;93(5):642-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Computed tomography and magnetic resonance images showed a markedly enhanced mass, 4 cm in diameter, on the anterior wall of the urinary bladder, which appeared to be adhesive to the pubic bone.
  • Under the suspicion of sarcoma of the urinary bladder, we performed anterior pelvic exenteration with construction of an ileal conduit.
  • The tumor corresponded to a fibrosarcoma that infiltrated the adipose tissue surrounding the urinary bladder.
  • The entire mucosa of the bladder showed diffuse squamous metaplasia, and well differentiated squamous cell carcinoma with pearl formation was found in part.
  • The patient developed a local relapse and pulmonary metastasis of fibrosarcoma one month postoperatively and died two month later without any response to chemotherapy (CYVADIC) and radiotherapy.
  • The current case seems to be the first one in Japan (third in the world) of a patient with multiple synchronous primary malignant tumors, carcinoma and sarcoma, airsing in the urinary bladder.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Fibrosarcoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12174642.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 12
  •  go-up   go-down


7. Italiano A, Delva F, Mathoulin-Pelissier S, Le Cesne A, Bonvalot S, Terrier P, Trassard M, Michels JJ, Blay JY, Coindre JM, Bui B: Effect of adjuvant chemotherapy on survival in FNCLCC grade 3 soft tissue sarcomas: a multivariate analysis of the French Sarcoma Group Database. Ann Oncol; 2010 Dec;21(12):2436-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of adjuvant chemotherapy on survival in FNCLCC grade 3 soft tissue sarcomas: a multivariate analysis of the French Sarcoma Group Database.
  • BACKGROUND: The predictive value of grade for benefit from adjuvant chemotherapy (AC) in soft tissue sarcoma (STS) patients has never been explored.
  • PATIENTS AND METHODS: From 1980 to 1999, 1513 adult patients with non-metastatic STS were included prospectively in the French Sarcoma Group database.
  • Grade was assessed according to the Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC) system after central review.
  • RESULTS: AC was delivered to 13 grade 1 patients (3%), 145 grade 2 patients (35%) and 262 grade 3 patients (62%).
  • Young age, non-well-differentiated liposarcoma histology, deep location, bone and/or neurovascular invasion and grade 2 or 3 were significantly associated with a higher likelihood to receive AC.
  • On multivariate analysis, AC was significantly associated with improved metastasis-free survival (MFS) [5-year MFS: 58% versus 49%, hazard ratio (HR) 0.7 (95% confidence interval (CI) 0.6-0.9), P = 0.01] and overall survival (OS) [5-year OS: 58% versus 45%, HR 0.6 (95% CI 0.5-0.8), P = 0.0002] in grade 3 patients.
  • This was not observed in grade 2 patients [5-year MFS: 76% versus 73%, HR 0.8 (95% CI 0.5-1.2), P = 0.27; 5-year OS: 75% versus 65%, HR 0.8 (95% CI 0.6-1.1), P = 0.15].
  • CONCLUSION: This large cohort-based analysis with long-term follow-up indicates that patients with FNCLCC grade 3 disease may benefit from AC.

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20439343.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Evaluation Studies; Journal Article; Multicenter Study
  • [Publication-country] England
  •  go-up   go-down


8. Lee DA, Harris CP, Gresik VM, Rao P, Lau CC: Granulocytic sarcoma presenting as pneumonia in a child with t(8;21) acute myelogenous leukemia: diagnosis by fluorescent in situ hybridization. J Pediatr Hematol Oncol; 2004 Jul;26(7):431-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granulocytic sarcoma presenting as pneumonia in a child with t(8;21) acute myelogenous leukemia: diagnosis by fluorescent in situ hybridization.
  • Granulocytic sarcoma is a soft tissue collection of leukemic cells.
  • Although he was initially diagnosed with nodular pneumonia, rapid resolution of a pulmonary infiltrate following induction chemotherapy was suggestive of a pulmonary granulocytic sarcoma.
  • Interphase fluorescent in situ hybridization (FISH) of the lung biopsy specimen for the t(8;21)(q22;q22) translocation confirmed the retrospective diagnosis of a well-differentiated pulmonary granulocytic sarcoma.
  • Pulmonary granulocytic sarcomas may be underrecognized in children with AML; this may delay anti-leukemic therapy and may lead to ineffective therapy if misdiagnosed as pneumonia.
  • [MeSH-major] Leukemia, Myeloid, Acute / pathology. Pneumonia / pathology. Sarcoma, Myeloid / pathology


9. Pellitteri PK, Ferlito A, Bradley PJ, Shaha AR, Rinaldo A: Management of sarcomas of the head and neck in adults. Oral Oncol; 2003 Jan;39(1):2-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These tumors exhibit variable growth and degrees of aggressiveness which are primarily dependent on histologic grade.
  • The pattern of growth demonstrated by sarcomas is generally by local advancement with high-grade tumor exhibiting extensive involvement of adjacent visceral and neurovascular structures.
  • The clinical presentation of these neoplasms is variable and dependent on subsite of involvement as well as the aggressiveness of tumor growth.
  • Treatment is predominantly surgical, utilizing wide local excision where en-bloc resection is feasible.
  • Chemotherapy regimens are available for soft tissue neoplasms and osteosarcoma and are primarily designed to improve local control.
  • Survival is predicted on the incidence of local recurrence and risk of distant metastasis, both of which are influenced by tumor grade.
  • Low-grade tumors exhibit improved survival over that of less differentiated tumors.
  • [MeSH-major] Head and Neck Neoplasms. Sarcoma
  • [MeSH-minor] Humans. Neoplasms, Radiation-Induced / etiology. Survival Analysis. Treatment Outcome


10. Gupta R, Sharma A, Arora R, Kulkarni MP, Chattopadhaya TK, Singh MK: Well-differentiated mesenteric liposarcoma with osseous metaplasia: a potential diagnostic dilemma for the pathologist. J Gastrointest Cancer; 2010 Mar;41(1):79-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Well-differentiated mesenteric liposarcoma with osseous metaplasia: a potential diagnostic dilemma for the pathologist.
  • BACKGROUND: Mesenteric liposarcoma is a rare intra-abdominal sarcoma with very few cases reported in the available English literature.
  • Dedifferentiation in liposarcoma manifests as a nonlipogenic sarcoma, which is usually high-grade and may show osteosarcomatous differentiation rarely.
  • To the best of our knowledge, osteoid metaplasia in a well-differentiated liposarcoma without evidence of dedifferentiation has not been documented in the available literature.
  • CASE: We describe the case of a middle-aged adult man with a well-differentiated liposarcoma of the mesentery.
  • At recurrence, the histological features were those of a well-differentiated liposarcoma with focal osseous metaplasia without any evidence of dedifferentiation in the extensive sections examined.
  • Such an occurrence in a recurrent well-differentiated liposarcoma is a perplexing problem due to the potential confusion with dedifferentiation.
  • This needs to be recognized to avoid overzealous chemotherapy and/or radiotherapy, which is required for dedifferentiated tumors.

  • Genetic Alliance. consumer health - Liposarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Intern Med. 2007;46(7):373-5 [17409600.001]
  • [Cites] Am J Surg Pathol. 1994 Nov;18(11):1150-7 [7943536.001]
  • [Cites] World J Gastroenterol. 2007 Aug 14;13(30):4147-8 [17696239.001]
  • [Cites] Skeletal Radiol. 2003 May;32(5):286-9 [12679843.001]
  • [Cites] Cancer. 2005 Aug 15;104(4):669-75 [16003776.001]
  • [Cites] Clin Neuropathol. 1996 Jan-Feb;15(1):60-2 [8998859.001]
  • [Cites] Jpn J Clin Oncol. 2006 Nov;36(11):735-8 [17000700.001]
  • [Cites] Semin Diagn Pathol. 2001 Nov;18(4):258-62 [11757865.001]
  • [Cites] AJR Am J Roentgenol. 1996 Apr;166(4):829-33 [8610559.001]
  • [Cites] Intern Med. 1998 Oct;37(10):884-90 [9840715.001]
  • [Cites] Surg Today. 1994;24(11):1003-6 [7772897.001]
  • (PMID = 20058101.001).
  • [ISSN] 1941-6636
  • [Journal-full-title] Journal of gastrointestinal cancer
  • [ISO-abbreviation] J Gastrointest Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Okoń K, Wierzchowski W, Jabłońska E, Wójcik P, Steczko A: Anaplastic, sarcomatoid carcinoma of the thyroid originating from a Hürthle cell tumor. Pol J Pathol; 2003;54(4):277-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sections of the tumor revealed a poorly differentiated malignant neoplasm.
  • An attempt at chemotherapy was made, but the patient died two months after the onset of the disease.
  • The histology revealed an anaplastic, sarcomatoid component, as well as a Hürthle cell carcinoma.
  • [MeSH-minor] Adult. Biomarkers, Tumor / metabolism. Diagnosis, Differential. Fatal Outcome. Female. Humans. Immunohistochemistry. Sarcoma / diagnosis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14998298.001).
  • [ISSN] 1233-9687
  • [Journal-full-title] Polish journal of pathology : official journal of the Polish Society of Pathologists
  • [ISO-abbreviation] Pol J Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


12. Bölke E, Ruf L, Budach W, Reinecke P, Röhrborn A, Pape H, Schwarz A, Schmitt G, Aul C: Tandem high-dose chemotherapy supported by autologous peripheral blood stem-cell transplantation and radiotherapy for recurrent malignant fibrous histiocytoma. Wien Klin Wochenschr; 2005 Dec;117(23-24):833-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tandem high-dose chemotherapy supported by autologous peripheral blood stem-cell transplantation and radiotherapy for recurrent malignant fibrous histiocytoma.
  • Malignant fibrous histiocytoma (MFH) is a soft-tissue sarcoma created from fibroblast cells and characterized by a high rate of metastasis or recurrence with poor prognosis.
  • We report a case of initially well differentiated (G1) MFH of the trunk in a 33-year-old woman.
  • Histopathological findings indicated a stromal tumor consisting of spindle cells, and immunohistochemical examination of resected specimens established the definite diagnosis of poorly differentiated MFH (G3).
  • There was a high local recurrence and metastasis rate, and the patient was treated with radiotherapy and conventional chemotherapy followed by tandem high-dose chemotherapy and peripheral blood stem-cell transplantation.
  • She is currently well seven years after the transplant, with no signs of metastasis and recurrence.
  • We review the clinical picture of the tumor in this patient and discuss its diagnosis, pathogenesis and treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Hematopoietic Stem Cell Transplantation. Histiocytoma, Malignant Fibrous / therapy. Radiotherapy. Soft Tissue Neoplasms / therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Doxorubicin / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Thoracic Surgery. Transplantation, Autologous. Treatment Outcome


13. Makhlouf HR, Ahrens W, Agarwal B, Dow N, Marshalleck JJ, Lee EL, Dotto JE, Hui P, Sobin LH, Oliveira A, Miettinen M: Synovial sarcoma of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 10 cases. Am J Surg Pathol; 2008 Feb;32(2):275-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synovial sarcoma of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 10 cases.
  • None of the patients had evidence of synovial sarcoma elsewhere.
  • Histologically, 9 tumors were monophasic one also having a poorly differentiated round cell component, and one was biphasic.
  • Two patients had received chemotherapy after surgery, but none had postoperative radiation.
  • Four patients with plaquelike or cuplike tumors < or =3 cm were alive and well 1, 2, 2, and 18.5 years after surgery.
  • One of them had a large 8-cm tumor, and another had a 2-cm tumor with a poorly differentiated component.
  • Synovial sarcoma rarely occurs as a gastric primary tumor.
  • [MeSH-major] Sarcoma, Synovial / genetics. Sarcoma, Synovial / pathology. Stomach Neoplasms / genetics. Stomach Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / genetics. Combined Modality Therapy. DNA, Neoplasm. Female. Gastrectomy. Humans. Male. Middle Aged. Molecular Biology. Neoplasm Recurrence, Local. Oncogene Proteins, Fusion / analysis. Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Synovial sarcoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18223331.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / Oncogene Proteins, Fusion; 0 / SYT-SSX fusion protein
  •  go-up   go-down


14. Kieback DG: Adenovirus-mediated thymidine kinase gene therapy induces apoptosis in human epithelial ovarian cancer cells and damages PARP-1. In Vivo; 2009 Jan-Feb;23(1):77-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenovirus-mediated thymidine kinase gene therapy induces apoptosis in human epithelial ovarian cancer cells and damages PARP-1.
  • Adenoviral (ADV) gene therapy with the thymidine kinase gene (TK) under control of the Rous sarcoma virus (RSV) promotor followed by the administration of acyclovir leads to replication errors in transcription and to cell death.
  • This concept of ADV-RSV-TK has been established for the treatment of ovarian cancer cells.
  • The purpose of this investigation was to clarify whether cell death after ADV-RSV-TK gene therapy and acyclovir administration is indeed due to apoptosis induction, whether the synergistic effect of ADV-RSV-TK gene therapy with chemotherapy was limited to the primary mechanism of action or whether the vector transduction itself exerted any pro-apoptotic effect was examined using the epithelial cell lines OVCAR-3 and MDAH-2774, established from human poorly differentiated serous ovarian cancer.
  • Fluorimetric assay of caspase-3 activity was performed, as well as ELISA of the CK 18 split product M30.
  • Apoptosis induction was established in this investigation as the mechanism of the ADV-RSV-TK gene therapy effect of acyclovir administration by caspase activity and subsequent CK 18 cleavage.
  • The synergistic effect of TK gene therapy and chemotherapeutic agents was shown to be TK induced.
  • Significant anti-PARP 1 activity was found to be an ADV-RSV-TK treatment effect after acyclovir addition.
  • [MeSH-major] Apoptosis / genetics. Cystadenocarcinoma, Serous / therapy. Genetic Therapy / methods. Ovarian Neoplasms / therapy. Poly(ADP-ribose) Polymerases / metabolism. Thymidine Kinase / genetics
  • [MeSH-minor] Acyclovir / pharmacology. Adenoviridae / genetics. Antiviral Agents / pharmacology. Cell Line, Tumor. Combined Modality Therapy. Drug Synergism. Female. Genetic Vectors. Humans. Rous sarcoma virus / genetics


15. Bradley JC, Caplan R: Giant retroperitoneal sarcoma: a case report and review of the management of retroperitoneal sarcomas. Am Surg; 2002 Jan;68(1):52-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant retroperitoneal sarcoma: a case report and review of the management of retroperitoneal sarcomas.
  • He underwent resection of a well-differentiated liposarcoma arising from his retroperitoneum measuring 50 cm and weighing 11.7 kg (25.8 lb).
  • This is the second largest retroperitoneal soft-tissue sarcoma (RSTS) that has been reported.
  • Diagnosis and treatment of RSTS can be extremely challenging for a general surgeon.
  • Treatment of RSTS remains surgical.
  • Multiple trials of chemotherapy and radiation therapy show no survival benefit.
  • The only successful treatment of this tumor is complete excision; 51.4 per cent of tumors can be completely excised, and 50.2 per cent of these excisions include adjacent organs.
  • With aggressive surgical therapy survival is increased to 58.0 and 39.6 per cent.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12467318.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 35
  •  go-up   go-down


16. Benjamin RS, Patel SR: Pediatric and adult osteosarcoma: comparisons and contrasts in presentation and therapy. Cancer Treat Res; 2009;152:355-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric and adult osteosarcoma: comparisons and contrasts in presentation and therapy.
  • Although the majority of adult patients with osteosarcoma are young adults, who might be treated in a similar fashion, experience derived from a slightly older population is helpful in directing therapy.
  • We treated a series of 123 patients with osteosarcoma of the extremities with adriamycin and cisplatin as induction therapy.
  • Sequential addition of methotrexate and methotrexate plus ifosfamide in subsequent cohorts improved the continuous relapse-free survival of poor responders such that overall survival improvement was noted in the group where therapy was modified by adding both agents to those with <90% tumor necrosis.
  • The variants, especially dedifferentiated parosteal osteosarcoma and dedifferentiated well-differentiated intraosseous osteosarcoma are more common in adults than children, accounting for some of the inferior prognosis in adults.
  • Older patients obviously cannot tolerate the doses of therapy given to children and young adults, again decreasing the chances of successful treatment.
  • An attempt to intensify therapy in poor-prognosis patients with a three-drug regimen of adriamycin, cisplatin, and ifosfamide with peripheral stem cell support was unsuccessful at prolonging relapse-free survival, and we no longer use that approach.
  • [MeSH-major] Bone Neoplasms / drug therapy. Osteosarcoma / drug therapy

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20213401.001).
  • [ISSN] 0927-3042
  • [Journal-full-title] Cancer treatment and research
  • [ISO-abbreviation] Cancer Treat. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


17. Peyrí Rey E, Urban Ramón A, Martínez Fernández M, Sanmarti Da Silva B: [Dedifferentiated liposarcoma of spermatic cord: degeneration of lipoma previously resected]. Actas Urol Esp; 2003 May;27(5):383-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These are usually large-sized tumours histologically characterised for being well-differentiated liposarcomas with some high grade sarcoma areas.
  • Volume, location, mass homogeneity as well as presence of pelvic and retroperitoneal adenopathies are reported by CT and ultrasound techniques.
  • These are useful for post-treatment follow-up.
  • Value of adjuvant radio- and chemotherapy is uncertain.
  • [MeSH-minor] Humans. Male. Middle Aged. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Liposarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12891917.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas espanolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


18. Benaragama KS, Neequaye SK, Maudgil D, Gordon AG: Small bowel liposarcoma--a rare cause of small bowel perforation. BMJ Case Rep; 2010;2010
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The histology demonstrated a well-differentiated liposarcoma.
  • Liposarcomas are the most common soft tissue sarcomas in adults but occurrence in the gastrointestinal tract is extremely rare.
  • Surgical resection with clear margins is the treatment of choice for primary liposarcomas.
  • They are moderately radiosensitive and chemotherapy is non-effective.

  • Genetic Alliance. consumer health - Liposarcoma.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Gastroenterol. 1972 Aug;58(2):172-6 [5056514.001]
  • [Cites] Ann Surg. 1974 Aug;180(2):175-9 [4843046.001]
  • [Cites] Acta Pathol Microbiol Scand Suppl. 1975;(253):1-71 [1059326.001]
  • [Cites] Am J Gastroenterol. 1988 Jan;83(1):89-92 [3337069.001]
  • [Cites] Tumori. 1993 Apr 30;79(2):77-91 [8346570.001]
  • [Cites] AJR Am J Roentgenol. 1995 Jan;164(1):129-34 [7998525.001]
  • [Cites] Ann Surg Oncol. 1999 Jun;6(4):389-94 [10379861.001]
  • [Cites] Int Surg. 1999 Apr-Jun;84(2):163-7 [10408290.001]
  • (PMID = 22791735.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3029041
  •  go-up   go-down


19. Goto T, Okuma T, Ogura K, Imanishi J, Hozumi T, Kondo T: [Indication of chemotherapy according to histological type of musculoskeletal sarcomas]. Gan To Kagaku Ryoho; 2009 Feb;36(2):199-203
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Indication of chemotherapy according to histological type of musculoskeletal sarcomas].
  • In high-grade musculoskeletal sarcomas, adjuvant chemotherapy is often performed to prevent distant metastases.
  • As the efficacy of chemotherapy varies according to the histological type of sarcoma, its indication is determined according to the histological type and the stage.
  • Prognoses are poor in patients with osteosarcoma, Ewing's sarcoma, or rhabdomyosarcoma, when surgery alone is performed.
  • However, because these sarcomas are chemosensitive, their prognoses are improved with adjuvant chemotherapy, so it is absolutely necessary.
  • Drugs commonly used for osteosarcoma include adriamycin, cisplatin, methotrexate, vincristine, and ifosfamide.
  • For Ewing's sarcoma and rhabdomyosarcoma, vincristine, actinomycin-D, cyclophosphamide, etoposide, and ifosfamide are commonly used.
  • On the other hand, the efficacy of chemotherapy is unclear in most of the non-round cell sarcomas, e. g., malignant fibrous histiocytoma, pleomorphic liposarcoma, and leiomyosarcoma, so adjuvant chemotherapy is relatively indicated and often performed preoperatively.
  • Postoperative chemotherapy is performed when the preoperative chemotherapy is effective.
  • Among them, the key drugs are adriamycin and ifosfamide.
  • For chemoresistant sarcomas, e. g., chondrosarcoma, chordoma, alveolar soft part sarcoma, chemotherapy is rarely indicated, even if the tumor is histologically high grade and large.
  • Low-grade musculoskeletal sarcomas, e. g., low-grade chondrosarcoma, central low-grade osteosarcoma, parosteal osteosarcoma, well-differentiated liposarcoma, and dermatofibrosarcoma protuberans, are well cured only by surgical excision, and adjuvant chemotherapy is therefore not indicated.
  • Superficially-located, small-size non-round cell sarcomas, even though histologically high grade, are well healed only by surgical excision, and adjuvant chemotherapy is rarely indicated.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Musculoskeletal Diseases / drug therapy. Musculoskeletal Diseases / pathology. Neoplasms, Muscle Tissue / drug therapy. Neoplasms, Muscle Tissue / pathology. Sarcoma / drug therapy. Sarcoma / pathology
  • [MeSH-minor] Combined Modality Therapy. Humans

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19223736.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


20. Thanakit V, Nelson SD, Udomsawaengsup S: Round cell liposarcoma of scrotum with indolent course in young adult. J Med Assoc Thai; 2005 Sep;88(9):1302-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Both myxoid and round cell types share clinical, histological features and are accepted to represent a spectrum of lesions ranging from pure myxoid to near completely round cell liposarcoma.
  • Round cell liposarcoma is highly metastatic and is classified as high grade and poorly differentiated myxoid sarcoma.
  • Most masses within the scrotal sac arise from the testis proper, and less likely from the extratesticular tissue.
  • Liposarcoma represents approximately 20% of malignant extratesticular neoplasms, with the well differentiated subtype being the most common.
  • Myxoid/round cell liposarcoma and round cell liposarcoma are rarely encounter in extratesticular soft tissue.
  • We reported a rare case of round cell liposarcoma (high grade myxoid liposarcoma) of extratesticular tissue.
  • To our knowledge, this is the first case of a large size (> 5cm) round cell liposarcoma arising from soft tissue within the scrotal sac of young adult with indolent course.
  • Simple excision or enucleation are inadequate therapies and wide excision of the hemiscrotum including inguinal soft tissue and nodes is recommended.
  • The role of retroperitoneal lymph node dissection and adjuvant chemotherapy remains controversial.

  • Genetic Alliance. consumer health - Liposarcoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16536120.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


21. Haberkorn U, Altmann A, Jiang S, Morr I, Mahmut M, Eisenhut M: Iodide uptake in human anaplastic thyroid carcinoma cells after transfer of the human thyroid peroxidase gene. Eur J Nucl Med; 2001 May;28(5):633-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Human thyroperoxidase (hTPO) is critical for the accumulation of iodide in thyroid tissues.
  • Poorly differentiated and anaplastic thyroid tumours which lack thyroid-specific gene expression fail to accumulate iodide and, therefore, do not respond to iodine-131 therapy.
  • Employing a bicistronic retroviral vector based on the myeloproliferative sarcoma virus for the transfer of the hTPO and the neomycin resistance gene, the C643 cells and SW1736 cells were transfected while the L2 cells and MH3924A cells were infected with retroviral particles.
  • Seven recombinant C643 and seven SW1736 cell lines as well as four recombinant L2 and four MH3924A cell lines were established by neomycin selection.
  • Genetically modified cell lines expressed up to 1,800 times more hTPO as compared to wild type tumour cells.
  • The transduction of the hTPO gene per se is not sufficient to restore iodide trapping in non-iodide-concentrating tumour cells.
  • [MeSH-minor] Animals. Drug Resistance / genetics. Genetic Vectors. Humans. Iodine Radioisotopes / therapeutic use. Liver Neoplasms, Experimental / metabolism. Neomycin / pharmacology. Rats. Retroviridae. Thyroglobulin / metabolism. Transfection. Tumor Cells, Cultured / drug effects. Tumor Cells, Cultured / metabolism

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. NEOMYCIN .
  • Hazardous Substances Data Bank. IODINE, ELEMENTAL .
  • Hazardous Substances Data Bank. THYROGLOBULIN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11383870.001).
  • [ISSN] 0340-6997
  • [Journal-full-title] European journal of nuclear medicine
  • [ISO-abbreviation] Eur J Nucl Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; 1404-04-2 / Neomycin; 9010-34-8 / Thyroglobulin; 9679TC07X4 / Iodine; EC 1.11.1.8 / Iodide Peroxidase
  •  go-up   go-down


22. Leyvraz S, Zweifel M, Jundt G, Lissoni A, Cerny T, Sessa C, Fey M, Dietrich D, Honegger HP, Swiss Group for Clinical Cancer Research: Long-term results of a multicenter SAKK trial on high-dose ifosfamide and doxorubicin in advanced or metastatic gynecologic sarcomas. Ann Oncol; 2006 Apr;17(4):646-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Dose intensive chemotherapy has not been tested prospectively for the treatment of gynecologic sarcomas.
  • We investigated the antitumor activity and toxicity of high-dose ifosfamide and doxorubicin, in the context of a multidisciplinary strategy for the treatment of advanced and metastatic, not pretreated, gynecologic sarcomas.
  • Salvage therapy was allowed after chemotherapy.
  • After a median of three (range 1-7) chemotherapy cycles, six patients experienced a complete response and 12 a partial response for an overall response rate of 49% (95% CI 32% to 66%).
  • The response rate was higher in poorly differentiated tumors (62%) compared with moderately well differentiated ones (18%), but was not different according to histology subtypes.
  • Eleven patients had salvage therapy, either immediately following chemotherapy (n = 7) or at time of progression (n = 4).
  • With a median follow-up time of 5 years, the median overall survival was 30.5 months.
  • Hematological toxicity was as expected neutropenia, thrombopenia and anemia > or = grade 3 at 50%, 34% and 33% of cycles respectively.

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16500907.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 80168379AG / Doxorubicin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


23. Yamamoto T, Marui T, Akisue T, Hitora T, Kawamoto T, Nagira K, Nakatani T, Yoshiya S, Kurosaka M: Management of liposarcoma occurring in pregnant women. Anticancer Res; 2003 Jan-Feb;23(1B):799-802
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: We present two cases of liposarcoma occurring in pregnant patients: one myxoid liposarcoma in a 29-year-old woman at 29 weeks' gestation; another well-differentiated liposarcoma in a 44-year-old woman at 22 weeks' gestation.
  • The patient was subsequently treated with chemotherapy and radiotherapy.
  • The second patient awaited delivery until 32 weeks' gestation with no treatment of the tumor because she had a low-grade sarcoma.
  • After cesarean section, surgical treatment followed.
  • CONCLUSION: Treatment of sarcomas occurring during pregnancy is difficult.
  • Both mother and fetus should be appropriately managed, depending on the trimester at the time of diagnosis and the histological type and grade of the tumor.
  • [MeSH-major] Liposarcoma / therapy. Pregnancy Complications, Neoplastic / therapy
  • [MeSH-minor] Adult. Cesarean Section. Combined Modality Therapy. Extremities. Female. Humans. Pregnancy. Pregnancy Outcome

  • Genetic Alliance. consumer health - Liposarcoma.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12680186.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


24. Jones RL, Fisher C, Al-Muderis O, Judson IR: Differential sensitivity of liposarcoma subtypes to chemotherapy. Eur J Cancer; 2005 Dec;41(18):2853-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential sensitivity of liposarcoma subtypes to chemotherapy.
  • Liposarcoma is one of the most common soft tissue sarcomas and has a number of different subtypes: well-differentiated; dedifferentiated; myxoid/round cell; and pleomorphic.
  • However, the response of these subgroups to chemotherapy is not well documented.
  • In this study, we have conducted a retrospective analysis of a prospectively maintained database of soft tissue sarcoma patients treated at the Royal Marsden Hospital.
  • Eighty-eight liposarcoma patients who received chemotherapy between August 1989 and June 2004 were identified.
  • The response rates to chemotherapy of the different histological subtypes and overall and progression free survival were investigated.
  • Survival according to histological grade was also assessed.
  • A statistically significant higher response rate to first-line chemotherapy was observed in patients with myxoid liposarcoma compared to de- and well-differentiated tumours, 48% (95%CI; 28-69) and 11% (95%CI; 2-29), P = 0.005.
  • Patients with lower grade tumours had better overall survival.
  • This retrospective analysis suggests that myxoid liposarcoma is relatively chemosensitive in comparison to a combination of other liposarcomas, and in particular de- and well-differentiated tumours.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Liposarcoma, Myxoid / drug therapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Prospective Studies. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Liposarcoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16289617.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


25. Lahat G, Anaya DA, Wang X, Tuvin D, Lev D, Pollock RE: Resectable well-differentiated versus dedifferentiated liposarcomas: two different diseases possibly requiring different treatment approaches. Ann Surg Oncol; 2008 Jun;15(6):1585-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resectable well-differentiated versus dedifferentiated liposarcomas: two different diseases possibly requiring different treatment approaches.
  • BACKGROUND: Division of retroperitoneal liposarcoma (RPLS) into well-differentiated (WD) and dedifferentiated (DD) subtypes is established; however, WD and DD are usually treated similarly.
  • We hypothesized that WD and DD have distinct biological behaviors mandating different treatments.
  • METHODS: A prospective sarcoma database identified all primary/recurrent RPLS treated between 1996 and 2007: 77 DD (52%) and 58 WD (39.2%) patients were analyzed for recurrence rate, recurrence free survival (RFS), and overall survival (OS).
  • A significant proportion of DD (37.7%) received chemotherapy compared to WD (1.7%; p < 0.0001).
  • Only 3.7% WD recurred as high grade metastatic disease.
  • Median time to recurrence was 55.5 months in WD versus 13.5 months in DD (p < 0.0001).
  • Gross total resection is achievable in most WD; unlike DD, high-grade recurrence is uncommon.
  • Treatment should therefore reflect these biologic differences by maximizing survivorship while avoiding unnecessarily extensive multivisceral resection.
  • SYNOPSIS: The biological behaviors of well-differentiated and dedifferentiated liposarcomas differ significantly.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg Oncol. 2008 Jun;15(6):1555-6 [18347875.001]
  • (PMID = 18398663.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


26. Papagelopoulos PJ, Mavrogenis AF, Badekas A, Sim FH: Foot malignancies: a multidisciplinary approach. Foot Ankle Clin; 2003 Dec;8(4):751-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant osseous and soft tissue tumors of the foot are rare and should be considered in patients who have foot-related symptoms.
  • In addition to benign and malignant neoplasms, pseudotumorous conditions mimic neoplastic lesions and should be differentiated before any treatment is undertaken.
  • The foot is a terminal anatomic structure, with closed and tight compartments and well-vascularized tissues, that predispose it to hematogenous and lymphatic metastases.
  • Patients who have a malignant foot tumor should be referred to an orthopedic oncologist for further evaluation and treatment.
  • The goals of treatment include local tumor control, restoration of function and stability during standing and walking, long-term survival, and improved quality of life.
  • Recent advances in chemotherapy and radiotherapy have allowed limb salvage procedures with wide tumor resections.
  • After tumor resection, reconstruction of the skeletal and soft tissue defects is possible by using bone allografts or vascularized autografts, arthrodesis, and free vascularized musculocutaneous flaps.
  • [MeSH-major] Bone Neoplasms / surgery. Foot Diseases / surgery. Sarcoma / surgery. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Combined Modality Therapy. Humans. Osteosarcoma / radiography. Osteosarcoma / surgery


27. Des Guetz G, De Mestier P, Pierga JY: [At last, an effective therapy for non-differentiated GI sarcomas (gastro intestinal stromal tumor)]. J Chir (Paris); 2002 Oct;139(5):268-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [At last, an effective therapy for non-differentiated GI sarcomas (gastro intestinal stromal tumor)].
  • [Transliterated title] Enfin un traitement efficace dans les sarcomes digestifs indifférenciés (tumeurs stromales).
  • Gastrointestinal stromal tumors (GISTs) are non differentiated sarcoma of the gastrointestinal tract and have for a long time been confused with well differentiated tumors and classified as leiomyosarcoma.
  • Recent studies have found that an inhibitor of specific tyrosine kinase is effective in the treatment of GIST with an estimated response rate of more than 60%.
  • This new drug could significantly improve the prognosis of these aggressive chemoresistant tumors.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Gastrointestinal Neoplasms / drug therapy. Piperazines / therapeutic use. Protein-Tyrosine Kinases / antagonists & inhibitors. Pyrimidines / therapeutic use. Sarcoma / drug therapy
  • [MeSH-minor] Adult. Benzamides. Diagnosis, Differential. Drug Resistance, Neoplasm. Humans. Imatinib Mesylate. Immunohistochemistry. Leiomyosarcoma / diagnosis. Middle Aged. Mutation. Prognosis. Proto-Oncogene Proteins c-kit / genetics. Randomized Controlled Trials as Topic. Stomach / pathology. Stomach Neoplasms / diagnosis. Stomach Neoplasms / drug therapy. Stomach Neoplasms / genetics. Stomach Neoplasms / pathology. Stomach Neoplasms / surgery. Time Factors

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Chir (Paris). 2002 Dec;139(6):368.
  • (PMID = 12410126.001).
  • [ISSN] 0021-7697
  • [Journal-full-title] Journal de chirurgie
  • [ISO-abbreviation] J Chir (Paris)
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  • [Number-of-references] 18
  •  go-up   go-down


28. Carrión López P, Pastor Navarro H, Martínez Ruiz J, Giménez Bachs JM, Donate Moreno MJ, Polo Ruiz L, Pastor Guzmán JM, Martínez Sanchiz C, Ruiz Mondéjar R, Virseda Rodríguez JA: [Spermatic cord sarcomas: current status and report of four cases]. Arch Esp Urol; 2009 Apr;62(3):242-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To study and review spermatic cord sarcomas, including symptoms, diagnosis, and treatment.
  • METHODS/RESULTS: We review the Spanish and international literature and report 4 new cases: 2 patients with well-differentiated spermatic cord liposarcomas (1 treated by simple tumorectomy), 1 patient with liposarcomatous degeneration of a previously excised atypical lipoma, and 1 patient operated for a malignant retroperitoneal fibrous histiocytoma with subsequent local recurrence in the paratesticular region.
  • They are diagnosed by imaging studies (ultrasound, computed tomography, magnetic resonance) and confirmed by histological examination.
  • Spermatic cord sarcomas are treated surgically; the efficacy of adjuvant treatments such as chemotherapy or radiation therapy is still under debate.
  • [MeSH-minor] Adolescent. Adult. Aged. Humans. Male. Middle Aged. Sarcoma

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19554782.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 12
  •  go-up   go-down


29. Müller CR, Paulsen EB, Noordhuis P, Pedeutour F, Saeter G, Myklebost O: Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A. Int J Cancer; 2007 Jul 1;121(1):199-205
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A.
  • However, Nutlin-based therapy could be even more important in more common sarcoma types where this aberration is frequent.
  • The well- and de-differentiated liposarcomas have complex marker chromosomes, consistently including multiple copies of the MDM2 locus.
  • We have therefore investigated the molecular response to Nutlin treatment in several liposarcoma cell lines with such markers, as well as a panel of other sarcoma cell lines.
  • Thus, Nutlin represents a promising new therapeutic principle for the treatment of an increasing group of sarcomas.
  • [MeSH-major] Imidazoles / pharmacology. Liposarcoma / drug therapy. Liposarcoma / pathology. Piperazines / pharmacology. Proto-Oncogene Proteins c-mdm2 / antagonists & inhibitors. Proto-Oncogene Proteins c-mdm2 / metabolism
  • [MeSH-minor] Apoptosis / drug effects. Cell Line, Tumor. Genotype. Humans. Sensitivity and Specificity. Signal Transduction. Tumor Suppressor Protein p53 / metabolism


30. Spillane AJ, A'Hern R, Judson IR, Fisher C, Thomas JM: Synovial sarcoma: a clinicopathologic, staging, and prognostic assessment. J Clin Oncol; 2000 Nov 15;18(22):3794-803
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synovial sarcoma: a clinicopathologic, staging, and prognostic assessment.
  • PURPOSE: Synovial sarcoma (SS) is a common soft tissue sarcoma (STS) with a propensity for young adults and notable sensitivity to chemotherapy (CT).
  • The problems with the current American Joint Committee for Cancer (AJCC) Staging System in relation to SS are discussed.
  • The current AJCC/International Union Against Cancer Staging System differentiated prognosis less well than the recently proposed Royal Marsden Hospital Staging System.
  • Therapeutic CT was administered to 55 patients.
  • SS is often chemosensitive, and given its poor prognosis, multicenter trials of adjuvant therapy are warranted.
  • [MeSH-major] Sarcoma, Synovial / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Databases, Factual. Disease-Free Survival. Female. Humans. Leg. Male. Middle Aged. Neoplasm Staging. Prognosis. Prospective Studies. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Synovial sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11078492.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


31. Zhang PJ, Brooks JS, Goldblum JR, Yoder B, Seethala R, Pawel B, Gorman JH, Gorman RC, Huang JH, Acker M, Narula N: Primary cardiac sarcomas: a clinicopathologic analysis of a series with follow-up information in 17 patients and emphasis on long-term survival. Hum Pathol; 2008 Sep;39(9):1385-95
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although cardiac sarcomas are rare in comparison to their soft tissue counterparts, they are the second most common type of primary cardiac neoplasm.
  • There were 6 angiosarcomas, 6 myxofibrosarcomas, 3 malignant peripheral nerve sheath tumors, 3 leiomyosarcomas, 2 synovial sarcomas, 1 epithelioid hemangioendothelioma, 1 chondrosarcoma, 1 osteosarcoma, and 4 poorly differentiated sarcomas.
  • The histologic grade was low in 4, moderate in 3, and high in 20 cases.
  • Six high-grade and 1 low-grade tumors were also treated with adjuvant chemotherapy and/or radiation.
  • In 17 patients with follow-up data, 6 of 12 patients with high-grade tumor died (4 within 5 days of the initial surgery, 1 in 21 months, and 1 in 131 months), and 1 patient with moderate-grade tumor and all 4 patients with low-grade tumor were alive without evidence of disease at the end of follow-up.
  • Tumor grade appeared to be prognostically important in cardiac sarcoma.
  • Long survival was achieved in patients who survived the initial surgery well.
  • [MeSH-major] Heart Neoplasms / pathology. Sarcoma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Infant. Male. Middle Aged. Survival Analysis

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Thorac Surg. 2000 Jun;69(6):1949-51 [10892961.001]
  • [Cites] Z Kardiol. 2002 Apr;91(4):352-6 [12063709.001]
  • [Cites] J Heart Lung Transplant. 2002 Oct;21(10):1135-9 [12398881.001]
  • [Cites] Rev Esp Cardiol. 2003 Apr;56(4):408-11 [12689577.001]
  • [Cites] Chest. 2003 May;123(5):1766-8 [12740300.001]
  • [Cites] Thorac Cardiovasc Surg. 2004 Apr;52(2):77-81 [15103579.001]
  • [Cites] Ann Surg. 1980 Feb;191(2):127-38 [7362282.001]
  • [Cites] Hum Pathol. 1982 Jul;13(7):640-5 [7084941.001]
  • [Cites] Cancer. 1984 Feb 1;53(3):530-41 [6692258.001]
  • [Cites] Arch Pathol Lab Med. 1985 Oct;109(10):943-5 [3840005.001]
  • [Cites] Chest. 1987 Jul;92(1):177-9 [3595230.001]
  • [Cites] Chest. 1987 Nov;92(5):860-2 [3665601.001]
  • [Cites] Thorac Cardiovasc Surg. 1990 Aug;38 Suppl 2:183-91 [2237900.001]
  • [Cites] Thorac Cardiovasc Surg. 1990 Aug;38 Suppl 2:192-5 [2237901.001]
  • [Cites] Ann Thorac Surg. 1991 Jun;51(6):906-10 [2039319.001]
  • [Cites] Ann Thorac Surg. 1991 Jun;51(6):999-1001 [2039335.001]
  • [Cites] Ann Thorac Surg. 1991 Oct;52(4):886-95 [1929651.001]
  • [Cites] Cancer. 1992 Jan 15;69(2):387-95 [1728367.001]
  • [Cites] Am Heart J. 1992 Jan;123(1):232-4 [1729836.001]
  • [Cites] Aust N Z J Med. 1991 Dec;21(6):881-3 [1818549.001]
  • [Cites] Scand J Thorac Cardiovasc Surg. 1992;26(3):233-6 [1287840.001]
  • [Cites] J Cardiovasc Surg (Torino). 1993 Dec;34(6):529-33 [8300722.001]
  • [Cites] Semin Surg Oncol. 1994 Sep-Oct;10(5):374-82 [7997732.001]
  • [Cites] J Heart Lung Transplant. 1995 Mar-Apr;14(2):382-6 [7779860.001]
  • [Cites] Hum Mol Genet. 1995 Jun;4(6):1097-9 [7655467.001]
  • [Cites] Histopathology. 1997 Apr;30(4):349-52 [9147083.001]
  • [Cites] Jpn Circ J. 1997 Sep;61(9):795-7 [9293411.001]
  • [Cites] Ann Diagn Pathol. 1998 Jun;2(3):167-72 [9845736.001]
  • [Cites] Br J Cancer. 1998 Dec;78(12):1624-8 [9862574.001]
  • [Cites] J Surg Oncol. 1999 Mar;70(3):194-8 [10102352.001]
  • [Cites] Histopathology. 1999 Apr;34(4):295-304 [10231396.001]
  • [Cites] Eur J Cardiothorac Surg. 2006 Jun;29(6):925-32 [16675225.001]
  • [Cites] J Thorac Oncol. 2006 Feb;1(2):188-9 [17409853.001]
  • [Cites] Gen Thorac Cardiovasc Surg. 2007 Jan;55(1):19-22 [17444167.001]
  • [Cites] Oncologist. 2007 Sep;12(9):1134-42 [17914083.001]
  • (PMID = 18602663.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL063954
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS522251; NLM/ PMC4081532
  •  go-up   go-down


32. Le Bouëdec G, Auvray H, Curé H, de Latour M, Penault-Llorca F, Dauplat J: [Uterine sarcoma in patients receiving tamoxifen therapy. Apropos of 2 cases]. Rev Med Interne; 2001 Sep;22(9):881-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Uterine sarcoma in patients receiving tamoxifen therapy. Apropos of 2 cases].
  • [Transliterated title] Sarcome utérin survenant au cours d'une hormonothérapie par tamoxifène. A propos de deux cas.
  • INTRODUCTION: Tamoxifen--a non steroidal triphenylethyl compound--in addition to having antiestrogenic properties may provoke weak estrogenic effects, the well known "paradoxical effects" on the female genital tractus.
  • Concern has been raised about prolonged tamoxifen treatment and subsequent occurrence of endometrial adenocarcinoma; subsequent attention has been drawn through high risk histologic subtypes including poorly differentiated patterns and uterine sarcomas.
  • EXEGESIS: We report two cases of uterine sarcoma arising in postmenopausal women taking tamoxifen, 20 mg daily during 38 and 42 months, for breast carcinoma: one leiomyosarcoma and one endometrial stromal sarcoma; both cases were asymptomatic and detected by pelvic sonography.
  • CONCLUSION: Further studies will be required to establish if there is a relationship between long term tamoxifen exposure and highly aggressive types of cancer of the uterine corpus exhibiting adverse histologic features such as uterine sarcomas.

  • Genetic Alliance. consumer health - Uterine sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11599191.001).
  • [ISSN] 0248-8663
  • [Journal-full-title] La Revue de medecine interne
  • [ISO-abbreviation] Rev Med Interne
  • [Language] FRE
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Estrogen Antagonists; 0 / Selective Estrogen Receptor Modulators; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


33. Arai H, Rino Y, Nishii T, Yukawa N, Wada N, Oshiro H, Ishida T, Nakaigawa N, Masuda M: Well-differentiated extraskeletal osteosarcoma arising from the retroperitoneum that recurred as anaplastic spindle cell sarcoma. Case Rep Med; 2010;2010:327591
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Well-differentiated extraskeletal osteosarcoma arising from the retroperitoneum that recurred as anaplastic spindle cell sarcoma.
  • Extraskeletal osteosarcoma is an uncommon high-grade malignant soft tissue sarcoma.
  • Well-differentiated extraskeletal osteosarcoma is thought to have a better prognosis than classical extraskeletal osteosarcoma, but dedifferentiation after recurrence has also been reported.
  • The histopathological diagnosis was well-differentiated retroperitoneal extraskeletal osteosarcoma.
  • She was followed up by CT every 6 months without adjuvant radiotherapy and chemotherapy for 31 months until anaplastic high-grade spindle cell sarcoma recurred in the retroperitoneum.
  • Our case is the seventh reported description of well-differentiated extraskeletal sarcoma, and the first to arise in the retroperitoneum and recur as an entirely dedifferentiated spindle cell sarcoma.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Radiol. 1991 Feb;64(758):171-2 [1900726.001]
  • [Cites] Arch Pathol Lab Med. 1991 Sep;115(9):906-9 [1929787.001]
  • [Cites] Cancer. 1990 Jun 15;65(12):2762-70 [2160317.001]
  • [Cites] Skeletal Radiol. 1989;18(6):471-4 [2814558.001]
  • [Cites] Cancer. 1987 Sep 1;60(5):1132-42 [3475157.001]
  • [Cites] Cancer. 1971 May;27(5):1121-33 [5281245.001]
  • [Cites] Hum Pathol. 2005 Apr;36(4):439-43 [15892008.001]
  • [Cites] Cancer. 1995 Dec 1;76(11):2253-9 [8635029.001]
  • [Cites] Am J Surg Pathol. 1998 May;22(5):588-94 [9591729.001]
  • [Cites] J Clin Pathol. 2001 Jan;54(1):77-8 [11271796.001]
  • [Cites] Skeletal Radiol. 2003 Mar;32(3):165-9 [12605283.001]
  • [Cites] Ann Surg. 1953 Nov;138(5):795-800 [13092816.001]
  • [Cites] J Natl Cancer Inst. 1995 Sep 6;87(17):1331-3 [7658488.001]
  • (PMID = 20224645.001).
  • [ISSN] 1687-9635
  • [Journal-full-title] Case reports in medicine
  • [ISO-abbreviation] Case Rep Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2833305
  •  go-up   go-down






Advertisement